REPORTING FROM ACTRIMS
Americas Committee for Treatment and Research in Multiple Sclerosis
West Palm Beach, Florida
FRIDAY, FEBRUARY 28
© 2020, Consortium of Multiple Sclerosis Centers. Published by Delaware Media Group, LLC. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or Bristol-Myers Squibb.
Oligodendrocytes are generators of myelin in the central nervous system, but inflammation of their precursor cells appears to limit remyelination in people with MS.Another compelling question is why attempts at promoting remyelination in MS have been unsuccessful to date. Remyelination of nerve cells is a normal function of the healthy brain, while demyelination is a hallmark of MS pathophysiology. Recent interest has focused on the role of oligodendrocyte precursor cells (OPCs), Dr. Calabresi said. Oligodendrocytes are glial cells essential in the production of myelin, but inflammation inhibits the ability of OPCs to mature into oligodendrocytes. "Suppressing this inflammation may offer a novel approach to treatment that directly address mechanisms of brain injury involved in MS." Dr. Calabresi suggested.